However, when combining the rigid hinge region with an engineered Fc domain stronger for FcγRIIB binding, anti-tumor activity significantly improved [45], indicating human CH1-hinge regions, selected for rigidity, and Fc domains engineered for FcγRIIB engagement can synergize to enhance the immunostimulatory and anti-tumor activities of antibodies targeting TNFR superfamily members. Here, SUCO is linked to neoplasm.